Research programme: monoclonal antibody therapeutics - BioAtla/BioDuro

Drug Profile

Research programme: monoclonal antibody therapeutics - BioAtla/BioDuro

Latest Information Update: 14 Jun 2015

Price : $50

At a glance

  • Originator BioAtla
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 11 Jun 2015 BioAtla has patent protection for Conditionally Active Biologic (CAB) technology
  • 17 Nov 2014 Early research in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top